drugset / Trial / NCT00210691
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to evaluate the long-term effectiveness of long-acting risperidone and its effect on quality of life
Timeline
- Start
- 1999-12
- Primary completion
- —
- Completion
- 2004-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 50 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 75 mg | Intramuscular |